Phase 3 Trial of Coronavir (Favipiravir) in Patients with Mild to Moderate COVID-19
Year: 2020
Type: preprint
Study designs: Randomized Controlled Trial, Clinical Trial
Source: SSRN Electronic Journal
DOI: 10.2139/ssrn.3696907
Authors: Tatiana Ruzhentsova, Pavel Chukhliaev, Daria Khavkina, Alexander Garbuzov, Rodion Oseshnyuk, Tatyana Soluyanova, Irina Shestakova, Adel Vafin, Elena Petrovna Dmitrikova, Dzhavanshir Mustafaev, Tatyana Domostroeva, Maria Otpushchennikova, Konstantin Pokrovsky, Тatyana Markova, Elena Kaplun, Diana Petina, Marina Rusanova, Dmitriy Bistritskiy, Natalia Kostina, Viсtoria Lesina, Sergey Scherbak, Alina Agafina, Yury Brook, Oleg Bronov, Evgeny Shults, Mikhail Samsonov, Emilia Krasavina, Arkadi Zintchenko, Maria Nikolskaya, Victoria Razzhivina, Olga Filon
Institutions: Gabrichevsky Institute of Epidemiology and Microbiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, City Clinical Hospital, Infectious Clinical Hospital No. 1, City Hospital No. 40, National Medical and Surgical Center named after N.I. Pirogov, Ministry of Health of the Russian Federation, Burdenko Neurosurgery Institute, R-Pharm (Russia)
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3102015759